Venous thromboembolic disease: Clinical practice guidelines in oncology

Michael B. Streiff; Paula L. Bockenstedt; Spero R. Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F. Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z. Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A. Jones; Nicole Kuderer; Jason T. Lee; Michael M. Millenson; Anne T. Neff; Thomas L. Ortel; Judy L. Smith; Gary C. Yee; Anaadriana Zakarija

doi:10.6004/jnccn.2011.0062

Venous thromboembolic disease: Clinical practice guidelines in oncology

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. SmithGary C. Yee, Anaadriana Zakarija

General Internal Medicine

Research output: Contribution to journal › Review article › peer-review

69 Scopus citations

Abstract

Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying VTE in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that cancer patients in a high-risk setting for VTE (e.g., patients who have undergone cancer surgery, those with multiple myeloma) continue to receive VTE prophylaxis, with the duration of anticoagulation determined by the clinical situation. Careful evaluation of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE, is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.

Original language	English (US)
Pages (from-to)	714-777
Number of pages	64
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	9
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2011.0062
State	Published - Jul 1 2011

Keywords

Anticoagulation
Cancer
Deep venous thrombosis
Heparin
Low-molecular-weight heparin
NCCN clinical practice guidelines
NCCN guidelines
Prophylaxis
Pulmonary embolism
Superficial vein thrombosis
Treatment
Venous thromboembolism
Warfarin

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2011.0062

Cite this

Streiff, M. B., Bockenstedt, P. L., Cataland, S. R., Chesney, C., Eby, C., Fanikos, J., Fogarty, P. F., Gao, S., Garcia-Aguilar, J., Goldhaber, S. Z., Hassoun, H., Hendrie, P., Holmstrom, B., Jones, K. A., Kuderer, N., Lee, J. T., Millenson, M. M., Neff, A. T., Ortel, T. L., ... Zakarija, A. (2011). Venous thromboembolic disease: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 9(7), 714-777. https://doi.org/10.6004/jnccn.2011.0062

Streiff, MB, Bockenstedt, PL, Cataland, SR, Chesney, C, Eby, C, Fanikos, J, Fogarty, PF, Gao, S, Garcia-Aguilar, J, Goldhaber, SZ, Hassoun, H, Hendrie, P, Holmstrom, B, Jones, KA, Kuderer, N, Lee, JT, Millenson, MM, Neff, AT, Ortel, TL, Smith, JL, Yee, GC & Zakarija, A 2011, 'Venous thromboembolic disease: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 9, no. 7, pp. 714-777. https://doi.org/10.6004/jnccn.2011.0062

@article{3c2200ae1a874fa4a997bc66ef2b210f,

title = "Venous thromboembolic disease: Clinical practice guidelines in oncology",

abstract = "Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying VTE in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that cancer patients in a high-risk setting for VTE (e.g., patients who have undergone cancer surgery, those with multiple myeloma) continue to receive VTE prophylaxis, with the duration of anticoagulation determined by the clinical situation. Careful evaluation of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE, is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.",

keywords = "Anticoagulation, Cancer, Deep venous thrombosis, Heparin, Low-molecular-weight heparin, NCCN clinical practice guidelines, NCCN guidelines, Prophylaxis, Pulmonary embolism, Superficial vein thrombosis, Treatment, Venous thromboembolism, Warfarin",

author = "Streiff, {Michael B.} and Bockenstedt, {Paula L.} and Cataland, {Spero R.} and Carolyn Chesney and Charles Eby and John Fanikos and Fogarty, {Patrick F.} and Shuwei Gao and Julio Garcia-Aguilar and Goldhaber, {Samuel Z.} and Hani Hassoun and Paul Hendrie and Bjorn Holmstrom and Jones, {Kimberly A.} and Nicole Kuderer and Lee, {Jason T.} and Millenson, {Michael M.} and Neff, {Anne T.} and Ortel, {Thomas L.} and Smith, {Judy L.} and Yee, {Gary C.} and Anaadriana Zakarija",

year = "2011",

month = jul,

day = "1",

doi = "10.6004/jnccn.2011.0062",

language = "English (US)",

volume = "9",

pages = "714--777",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "7",

}

TY - JOUR

T1 - Venous thromboembolic disease

T2 - Clinical practice guidelines in oncology

AU - Streiff, Michael B.

AU - Bockenstedt, Paula L.

AU - Cataland, Spero R.

AU - Chesney, Carolyn

AU - Eby, Charles

AU - Fanikos, John

AU - Fogarty, Patrick F.

AU - Gao, Shuwei

AU - Garcia-Aguilar, Julio

AU - Goldhaber, Samuel Z.

AU - Hassoun, Hani

AU - Hendrie, Paul

AU - Holmstrom, Bjorn

AU - Jones, Kimberly A.

AU - Kuderer, Nicole

AU - Lee, Jason T.

AU - Millenson, Michael M.

AU - Neff, Anne T.

AU - Ortel, Thomas L.

AU - Smith, Judy L.

AU - Yee, Gary C.

AU - Zakarija, Anaadriana

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying VTE in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that cancer patients in a high-risk setting for VTE (e.g., patients who have undergone cancer surgery, those with multiple myeloma) continue to receive VTE prophylaxis, with the duration of anticoagulation determined by the clinical situation. Careful evaluation of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE, is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.

AB - Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying VTE in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that cancer patients in a high-risk setting for VTE (e.g., patients who have undergone cancer surgery, those with multiple myeloma) continue to receive VTE prophylaxis, with the duration of anticoagulation determined by the clinical situation. Careful evaluation of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE, is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.

KW - Anticoagulation

KW - Cancer

KW - Deep venous thrombosis

KW - Heparin

KW - Low-molecular-weight heparin

KW - NCCN clinical practice guidelines

KW - NCCN guidelines

KW - Prophylaxis

KW - Pulmonary embolism

KW - Superficial vein thrombosis

KW - Treatment

KW - Venous thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=79960092301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960092301&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2011.0062

DO - 10.6004/jnccn.2011.0062

M3 - Review article

C2 - 21715723

AN - SCOPUS:79960092301

SN - 1540-1405

VL - 9

SP - 714

EP - 777

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 7

ER -

Venous thromboembolic disease: Clinical practice guidelines in oncology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this